Ubrogepant Patent Expiration
Ubrogepant is Used for the acute treatment of migraines in adults with or without aura, including those with severe hepatic or renal impairment. It was first introduced by Abbvie Inc
Ubrogepant Patents
Given below is the list of patents protecting Ubrogepant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ubrelvy | US11717515 | Treatment of migraine | Dec 22, 2041 | Abbvie |
| Ubrelvy | US11857542 | Treatment of migraine | Dec 22, 2041 | Abbvie |
| Ubrelvy | US12070450 | Treatment of migraine | Dec 22, 2041 | Abbvie |
| Ubrelvy | US10117836 | Tablet formulation for CGRP active compounds | Jan 30, 2035 | Abbvie |
| Ubrelvy | US11925709 | Tablet formulation for CGRP active compounds | Jan 30, 2035 | Abbvie |
| Ubrelvy | US8912210 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Dec 23, 2033 | Abbvie |
| Ubrelvy | US8754096 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Jul 19, 2032 | Abbvie |
| Ubrelvy | US9499545 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Nov 10, 2031 | Abbvie |
| Ubrelvy | US9833448 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Nov 10, 2031 | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ubrogepant's patents.
Latest Legal Activities on Ubrogepant's Patents
Given below is the list recent legal activities going on the following patents of Ubrogepant.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9499545 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Mar, 2024 | US11925709 |
| Email Notification Critical | 22 Feb, 2024 | US11925709 |
| Issue Notification Mailed Critical | 21 Feb, 2024 | US11925709 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US9499545 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US8754096 |
| Dispatch to FDC | 09 Feb, 2024 | US11925709 |
| Application Is Considered Ready for Issue Critical | 09 Feb, 2024 | US11925709 |
| Issue Fee Payment Received Critical | 05 Feb, 2024 | US11925709 |
| Issue Fee Payment Verified Critical | 05 Feb, 2024 | US11925709 |
Ubrogepant's Family Patents
